A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.

Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N

The journal of obstetrics and gynaecology research1 Oct 2000Cited by 42 (Europe PMC)

PMID11147718DOI10.1111/j.1447-0756.2000.tb01334.xPepBankPUB-11147718

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialSafety outcome
In patients with leiomyomas or endometriosis, leuprolide caused less menstruation-like bleeding than buserelin at 8 weeks (p < 0.01).
In plain wordsIn patients with leiomyomas or endometriosis, bleeding was less frequent with leuprolide than buserelin at 8 weeks.
Peptide
Leuprolide
Outcome
DecreaseGenital bleeding at 8 weeks
Study
n = 67
Comparator
Buserelin MP 1.8 mg
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
The incidence of menstruation-like genital bleeding 8 weeks after treatment was significantly (p < 0.01) higher in Group B.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771801
02HumanRandomized controlled trialSafety outcome
In patients with leiomyomas or endometriosis, the bleeding difference between leuprolide and buserelin disappeared by 12 weeks.
In plain wordsIn patients with leiomyomas or endometriosis, the bleeding difference between leuprolide and buserelin disappeared by 12 weeks.
Peptide
Leuprolide
Outcome
No significant changeGenital bleeding at 12 weeks
Study
n = 67
Comparator
Buserelin MP 1.8 mg
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
However this difference disappeared by 12 weeks after treatment.
4 context sentences(design, population, supporting numbers)
Summary · context
The incidence of menstruation-like genital bleeding 8 weeks after treatment was significantly (p < 0.01) higher in Group B.
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771802
03HumanRandomized controlled trialSafety outcome
In patients with leiomyomas or endometriosis, hot flashes were significantly more severe with leuprolide than buserelin (p < 0.01), and this tendency continued until 20 weeks.
In plain wordsIn patients with leiomyomas or endometriosis, leuprolide caused more severe hot flashes than buserelin.
Peptide
Leuprolide
Outcome
IncreaseHot flash severity
Study
n = 67
Comparator
Buserelin MP 1.8 mg
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
The climacteric symptom of hot flashes was found to be significantly (p < 0.01) more severe in Group L, and this tendency continued until 20 weeks after treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771803
04HumanRandomized controlled trialEfficacy outcome
In patients with leiomyomas or endometriosis, serum LH at 8 weeks did not differ significantly between leuprolide and buserelin.
In plain wordsIn patients with leiomyomas or endometriosis, LH levels did not differ significantly between leuprolide and buserelin.
Peptide
Leuprolide
Outcome
No significant changeSerum LH
Study
n = 67
Comparator
Buserelin MP 1.8 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
The 2 groups did not differ significantly with regard to the levels of the serum LH, FSH, and estradiol at 8 weeks after treatment or in the endometrial thickness at the end of the GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771804
05HumanRandomized controlled trialEfficacy outcome
In patients with leiomyomas or endometriosis, serum FSH at 8 weeks did not differ significantly between leuprolide and buserelin.
In plain wordsIn patients with leiomyomas or endometriosis, FSH levels did not differ significantly between leuprolide and buserelin.
Peptide
Leuprolide
Outcome
No significant changeSerum FSH
Study
n = 67
Comparator
Buserelin MP 1.8 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
The 2 groups did not differ significantly with regard to the levels of the serum LH, FSH, and estradiol at 8 weeks after treatment or in the endometrial thickness at the end of the GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771805
06HumanRandomized controlled trialEfficacy outcome
In patients with leiomyomas or endometriosis, estradiol at 8 weeks did not differ significantly between leuprolide and buserelin.
In plain wordsIn patients with leiomyomas or endometriosis, estradiol levels did not differ significantly between leuprolide and buserelin.
Peptide
Leuprolide
Outcome
No significant changeSerum estradiol
Study
n = 67
Comparator
Buserelin MP 1.8 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
The 2 groups did not differ significantly with regard to the levels of the serum LH, FSH, and estradiol at 8 weeks after treatment or in the endometrial thickness at the end of the GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771806
07HumanRandomized controlled trialEfficacy outcome
In patients with leiomyomas or endometriosis, endometrial thickness did not differ significantly between leuprolide and buserelin at treatment completion.
In plain wordsIn patients with leiomyomas or endometriosis, endometrial thickness did not differ significantly between leuprolide and buserelin.
Peptide
Leuprolide
Outcome
No significant changeEndometrial thickness
Study
n = 67
Comparator
Buserelin MP 1.8 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
The 2 groups did not differ significantly with regard to the levels of the serum LH, FSH, and estradiol at 8 weeks after treatment or in the endometrial thickness at the end of the GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771807
08HumanNon-randomized trialEfficacy outcome
In patients with uterine leiomyomas, volume decreased after leuprolide treatment, as it did with buserelin (p < 0.01).
In plain wordsIn patients with uterine leiomyomas, tumor volume decreased after leuprolide treatment, as it did with buserelin.
Peptide
Leuprolide
Outcome
DecreaseLeiomyoma volume
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
In both groups, the volumes of the uterine leiomyomas were significantly (p < 0.01) lower after the treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771808
09HumanNon-randomized trialEfficacy outcome
In patients with endometrial cysts, cyst volume did not decrease after leuprolide treatment, as with buserelin.
In plain wordsIn patients with endometrial cysts, cyst volume did not decrease after leuprolide treatment, as with buserelin.
Peptide
Leuprolide
Outcome
Direction not reportedEndometrial cyst volume
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.88 mg every 28 daysAs given in this study (human).
Source sentences
Summary
In contrast, the volumes of the endometrial cysts did not decrease after administration of GnRHa in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective randomized study involving 67 patients with uterine leiomyomas or endometriosis was carried out.
Summary · context
These patients were randomly administered either buserelin MP 1.8 mg (Group B, n = 34) or leuprolide 1.88 mg (Group L, n = 33).
Summary · context
The GnRHa depot was administered from 3 to 8 times, 28 days apart, in both groups.
Report a problemFND-1114771809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms